Showing results (51-60 of 61) with videos related to
Sort By:
Pageof 7
European Journal of Cancer (Oxford, England : 1990)|July 8, 2020
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trialBenedetta Conte, Marco Bruzzone, Matteo Lambertini, et al.Breast (Edinburgh, Scotland)|June 27, 2026
Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trialChiara Molinelli, Virginia Delucchi, Eva Blondeaux, et al.Breast Cancer Research and Treatment|October 25, 2023
Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in BelgiumMariana Brandão, Diogo Martins-Branco, Claudia De Angelis, et al.Breast (Edinburgh, Scotland)|July 23, 2024
Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER studyLuca Arecco, Maria Maddalena Latocca, Eva Blondeaux, et al.Journal of the National Cancer Institute|May 5, 2022
Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted TherapyMatteo Lambertini, Shona Fielding, Sibylle Loibl, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2018
Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level DataMatteo Lambertini, Halle C F Moore, Robert C F Leonard, et al.The Lancet. Oncology|September 20, 2021
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trialLucia Del Mastro, Mauro Mansutti, Giancarlo Bisagni, et al.European Journal of Cancer (Oxford, England : 1990)|February 6, 2026
Comparison of suboptimal versus adequate ovarian function suppression in premenopausal women with early breast cancer treated with adjuvant endocrine therapy: An exploratory analysis of two prospective studiesSimone Nardin, Marco Bruzzone, Luca Arecco, et al.The Lancet. Oncology|November 12, 2022
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trialLucia Del Mastro, Francesca Poggio, Eva Blondeaux, et al.Eclinicalmedicine|May 31, 2023
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studiesMatteo Lambertini, Eva Blondeaux, Giancarlo Bisagni, et al.Pageof 7